SQZ Biotech CEO to Participate in BIO International Panel and to Present at Investor Conferences in Second Quarter 2018

WATERTOWN, Mass., May 15, 2018 /PRNewswire/ -- SQZ Biotechnologies (SQZ), a biotechnology company developing novel cellular therapies for multiple indications, announced today that Armon Sharei, PhD, SQZ's co-founder and CEO, will be participating in a panel at the 2018 BIO International Convention, taking place in Boston, MA, June 4-7, 2018. SQZ management also will be presenting at two investor conferences in the second quarter of 2018.

The Company has an ongoing collaboration with F.Hoffmann-La Roche Ltd ("Roche") that began in 2015. Both companies will be sitting on the panel at BIO that will focus on international partnerships. "BIO is a great platform for fostering collaboration," said Dr. Sharei, "and I am delighted to have the opportunity to join the panel and comment on our partnership with Roche."

About SQZ Biotech
Through internal research programs and external partnerships, SQZ's unique cell engineering capabilities are being used to develop a new generation of cell therapies. SQZ's current internal efforts are focused on the development of novel, cell-based, immune therapies that leverage targeted immune modulation to impact oncology and autoimmune disease applications. For more information please visit www.sqzbiotech.com.

SQZ Contact: 
Rebecca Cohen 
Manager, Corporate Relations & Administration 
[email protected] 
617-758-8672 ext. 728

SQZ Media Contact:
Justin Jackson
Burns McClellan 
212-213-0006, ext. 327 
[email protected]

SOURCE SQZ Biotechnologies

Related Links

http://www.sqzbiotech.com